Mahesh Swaminathan, M.B., B.S.

Peer-Reviewed Articles

1. Swaminathan M, Ravandi F. Can Measurable Residual Disease (MRD) assessment be reliably used to defer allogeneic stem cell transplant in patients with intermediate-risk acute myeloid leukemia?. Haematologica 108(10):2561-2563, 2023. e-Pub 2023. PMID: 37345488.
2. Swaminathan M, Aly MM, Khan AM, Share BA, Dhillon V, Lalo E, Ramos H, Akers KG, Kim S, Balasubramanian S. Efficacy analysis of different FLT3 inhibitors in patients with relapsed/refractory acute myeloid leukemia and high-risk myelodysplastic syndrome. EJHaem 4(1):165-173, 2023. e-Pub 2022. PMID: 36819163.
3. Swaminathan M, Cortes JE. Update on the role of gemtuzumab-ozogamicin in the treatment of acute myeloid leukemia. Ther Adv Hematol 14:20406207231154708, 2023. e-Pub 2023. PMID: 36845850.
4. Singh A, Mencia-Trinchant N, Griffiths E, Altahan A, Swaminathan M, Gupta M, Gravina M, Tajammal R, Faber M, Yan L, Sinha E, Hassane D, Hayes DN, Guzman M, Iyer R, Wang E, Thota S. Mutant PPM1D-and TP53-Driven Hematopoiesis Populates the Hematopoietic Compartment in Response to Peptide Receptor Radionuclide Therapy. JCO Precision Oncology 6, 2022.
5. Swaminathan M, Bourgeois W, Armstrong SA, Wang ES. Menin Inhibitors in Acute Myeloid Leukemia-What Does the Future Hold?. Cancer J 28(1):62-66, 2022. PMID: 35072375.
6. Swaminathan M, Kantarjian HM, Levis M, Guerra V, Borthakur G, Alvarado Y, DiNardo CD, Kadia T, Garcia-Manero G, Ohanian M, Daver N, Konopleva M, Pemmaraju N, Ferrajoli A, Andreeff M, Jain N, Estrov Z, Jabbour EJ, Wierda WG, Pierce S, Pinsoy MR, Xiao L, Ravandi F, Cortes JE. A phase I/II study of the combination of quizartinib with azacitidine or low-dose cytarabine for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Haematologica 106(8):2121-2130, 2021. e-Pub 2021. PMID: 33853292.
7. Swaminathan M, Wang ES. Novel therapies for AML: a round-up for clinicians. Expert Rev Clin Pharmacol 13(12):1389-1400, 2020. e-Pub 2021. PMID: 33412978.
8. Bose P, Swaminathan M, Pemmaraju N, Ferrajoli A, Jabbour EJ, Daver NG, DiNardo CD, Alvarado Y, Yilmaz M, Huynh-Lu J, Qiao W, Wang X, Matamoros A, Zhou L, Pierce S, Schroeder KD, Kantarjian HM, Verstovsek S. A phase 2 study of pracinostat combined with ruxolitinib in patients with myelofibrosis. Leuk Lymphoma 60(7):1767-1774, 2019. e-Pub 2019. PMID: 30632841.
9. Swaminathan M, Bannon SA, Routbort M, Naqvi K, Kadia TM, Takahashi K, Alvarado Y, Ravandi-Kashani F, Patel KP, Champlin R, Kantarjian H, Strong L, DiNardo CD. Hematologic malignancies and Li-Fraumeni syndrome. Cold Spring Harb Mol Case Stud 5(1), 2019. e-Pub 2019. PMID: 30709875.
10. Swaminathan M, Borthakur G, Kadia T, Ferrajoli A, Alvarado Y, Yilmaz M, Huynh-Lu J, Qiao W, Wang X, Matamoros A, Zhou L, Pierce S, Schroeder K, Kantarjain H, Verstovsek S. A phase 2 clinical trial of eltrombopag for treatment of patients with myelodysplastic syndromes after hypomethylating-agent failure. Leukemia & lymphoma 1(7), 2019.
11. Swaminathan M, Patel K, Huynh-Lu J, Tang G, Zuo Z, Miranda R, Verstovsek S. Unique Case of Myeloproliferative Neoplasm with Two Rare Clonal Abnormalities: Rare JAK2 Exon 12 Mutation and Rare e14a3 (b3a3) BCR/ABL Fusion Transcript. Acta haematologica 141(1):23-27, 2018.
12. Bose P, Swaminathan M. JAK inhibition and symptom control in myeloproliferative neoplasms. Current Medical Research and Opinion 1(3), 2018.
13. Abeer A, Swaminathan M, Kumar, J. Sweet Mystery Case Report of a Rare Presentation of Myelodysplastic Syndrome as the Sweet’s Syndrome. Scientific Open Access 1(1):3, 2017.
14. Swaminathan M, Jensen, T., Ray, T., Andruska, N., Shah, A., Egner, J., Ray P.. FOXC1 expression in acute myeloid leukemia: potential predictor of disease relapse and/or refractory disease. Blood 128(22):5260, 2016.
15. Abeer, A., Swaminathan M, Kumar, J.. The Difficult Diagnosis: Late Onset Antiphospholipid Antibody Syndrome. Austin Emerg Med 3(1):1052, 2016.
16. Calvaresi E, Swaminathan M, Jokela J. A Case of May-Thurner Syndrome. Carle Sel Pap 59(1):46-47, 2016. PMID: 27489392.

Abstracts

1. Swaminathan M, Fazal S, Griffiths E, Thompson J, Sung PJ, Green SD, Li E, Said M, Belko K, Mattice E, Attwood K, Wang E. A phase II study of CPX-351 in younger patients < 60 years old with secondary acute myeloid leukemia: Trial in progress. Presented at ASH, 2022.
2. Swaminathan M, Aly MM, Akers K, Kijm S, Balasubramanian S. Efficacy analysis of different FLT3 inhibitors in patients with relapsed/refractory acute myeloid leukemia and high-risk myelodysplastic syndrome – a systematic review and meta-analysis. Poster presentation at ASH, 2021.
3. Singh A, Mencia-Trinchant N, Griffiths EA, Swaminathan M, Gravina M, Tajammal R, Faber M, Ernstoff M, Yan L, Sinha E, Herr M, Hassane D, Guzman M, Przespolewski A, Wang E, Thota S. DNMT3A and TET2 mutant Clonal Hematopoiesis May Drive a Proinflammatory State and Predict Enhanced Response to Immune Checkpoint Inhibitor. Blood 138(Suppl 1), 2021.
4. Aly MM, Swaminathan M, Akers K, Kim S, Ramos H, Maciejewski J, Balasubramanian SK. A Systematic Review and Meta-Analysis Comparing Type I and II FLT3 Inhibitors in Relapsed/Refractory Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome. Blood 138(Suppl 1), 2021.
5. Swaminathan M, Przespolewski A, Griffiths E, Thompson J, Elshoury A, Walinski W, Wang E. Phase I Dose-Finding Study of Eltrombopag Following High Dose Cytarabine and Mitoxantrone Chemotherapy in Patients with Relapsed/Refractory Acute Myeloid Leukemia. Blood 138(Suppl 1), 2021.
6. Swaminathan M, Przespolewski A, Griffiths E, Thompson J, Elshoury A, Walinski W, Said M, Halliwell S, Puff C, Attwood K, Wang E. Phase I Trial of Talazoparib and Gemtuzumab Ozogamicin in Adult Patients with CD33+ Relapsed or Refractory Acute Myeloid Leukemia. Blood 138(Suppl 1), 2021.
7. Pandey M, Swaminathan M, Griffiths E, Thompson J, Przespolewski A, Thota S, Baron, J, Cronin T, Wang E. Outcomes of Venetoclax-Based Regimens Compared with Hypomethylating Agents (HMA) Alone or 7+ 3 in Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia (AML): A Single Center Retrospective Analysis. Blood 134(Suppl 1), 2019.
8. Swaminathan M, Jabbour E, Ravandi F, Kadia T, Borthakur G, Short NJ, Poerce S, Waukau, J Miller D, Cortes J, Alvarado Y, Kantarjian H, Garcia-Manero G. Association of early intervention in transfusion independent patients with lower-risk myelodysplastic syndromes treated with attenuated doses of hypomethylating agents with high response rates and long duration of response. J Clin Oncol 36(15):7001, 2018.
9. Swaminathan M, Jabbour E, Ravandi F, Kadia T, Borthakur G, Konopleva M, DiNardo C, Pierce S, Alvarado Y, Assi RE, Dalle I, Tallis E, Kantarjain H, Garcia-Manero G. Outcomes of Patients with Nucleoplasmin-1 Mutated Acute Myeloid Leukemia Treated With Hypomethylating Agents. J Clin Oncol 36(15):7054, 2018.
10. Swaminathan M, Kantarjian H, Daver N, Borthakur B, Ohanian M, Kadia T, DiNardo C, Jain N, Estrov Z, Ferrajoli A, Garcia-Manero G, Konopleva M, Andreeff M, Pemmaraju N, Jabbour E, Wierda W, Pinsoy MR, Cortes J. The Combination of Quizartinib with Azacitidine or Low Dose Cytarabine Is Highly Active in Patients (Pts) with FLT3-ITD Mutated Myeloid Leukemias: Interim Report of a Phase I/II Trial. Blood 130(Suppl 1):723, 2017.
11. Boddu P, Swaminathan M, Ravandi F, Garcia-Manero G, Borthakur G, Jabbour E, DiNardo C, Daver N, Jain N. Prognostic Implications of Minimal Residual Disease Detection in Acute Myeloid Leukemia (AML) with Cytarabine Based Therapy of Differing Dose Intensities. Blood 130(Suppl 1), 2017.
12. Ravindra, S, Swaminathan M. A Rare Case of Abdominal Amyloidosis. Poster presentation at Research Day; Champaign, IL, 2016.
13. Swaminathan M, Arain A, Kumar J.. A Case of Carcinomatous Polyarthritis. Poster presentation at ACP downstate Peoria, IL, 2016.
14. Swaminathan M, Jokela, J.. The Forgotten Disease. Poster presentation at ACP downstate Peoria, IL, 2015.
15. Swaminathan M, Zhang M. A Rare Case of IgM Multiple Myeloma. Poster presentation at ACP downstate Peoria, IL, 2015.